Spectrum gets FDA response letter on cancer drug
Posted 10-09-2009 at 02:07 PM by admin
Fri Oct 9, 2009 7:01am EDT
* Says will request meeting with FDA
* Says FDA did not request changes to current indications
Oct 9 (Reuters) - Spectrum Pharmaceuticals (SPPI.O) said it received a complete response letter from U.S. health regulators regarding its supplementary marketing application for its drug, Fusilev, to treat advanced metastatic colorectal cancer.
Spectrum, which received marketing approval for its another cancer drug last month, said it plans to request a meeting with the U.S. Food and Drug Administration to discuss options for approval of Fusilev.
Fusilev is currently approved by the FDA as a rescue after high dose of methotrexate therapy in patients with osteosarcoma, a type of bone cancer.
Fusilev is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonist, a type of chemotherapy.
Read the rest of the article here.
© Thomson Reuters 2009 All rights reserved
* Says will request meeting with FDA
* Says FDA did not request changes to current indications
Oct 9 (Reuters) - Spectrum Pharmaceuticals (SPPI.O) said it received a complete response letter from U.S. health regulators regarding its supplementary marketing application for its drug, Fusilev, to treat advanced metastatic colorectal cancer.
Spectrum, which received marketing approval for its another cancer drug last month, said it plans to request a meeting with the U.S. Food and Drug Administration to discuss options for approval of Fusilev.
Fusilev is currently approved by the FDA as a rescue after high dose of methotrexate therapy in patients with osteosarcoma, a type of bone cancer.
Fusilev is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonist, a type of chemotherapy.
Read the rest of the article here.
© Thomson Reuters 2009 All rights reserved
Total Comments 0
Comments
Recent Blog Entries by admin
- Research and Markets: Market of Paclitaxel Injection in China (08-20-2010)
- Relief for cancer patients may be 2,000 years old (08-20-2010)
- Melanoma Research Alliance Announces $5.2 Million in New Grants (08-20-2010)
- Melanoma Research Alliance Announces $5.2 Million in New Grants to Support Six Innova (08-20-2010)
- Breast cancer survivors don't need to be afraid of air travel: U of A study (08-20-2010)
